How much cheaper is continuous manufacturing than fed-batch?

Compared to an optimized best-in-class fed-batch process at 15 g/L titer with multicolumn chromatography, end-to-end continuous manufacturing reduces total annual production costs by up to 23%, facility footprint by up to 51%, and facility capital cost by 30 to 50%. The advantage is larger when the comparison is against a lower-titer fed-batch baseline. These figures come from economic modeling of a multiproduct facility producing clinical and commercial lots; actual savings depend on program-specific titer, scale, and demand profile.

What is the main cost disadvantage of continuous manufacturing versus fed-batch?

Perfusion media consumption is the primary operating cost disadvantage. A continuous perfusion bioreactor running at steady state consumes roughly one full bioreactor volume of medium per day, meaning a 1,000-liter bioreactor uses 365,000 liters of specialized perfusion medium per year. This cost is offset by the higher volumetric productivity of the smaller bioreactor, but the net economic balance depends on the product titer, media cost per liter, and the annual volume being produced.

What is the hybrid approach to process intensification and when is it preferred?

The hybrid approach combines fed-batch upstream cell culture with continuous downstream capture and polishing chromatography. It captures the productivity gains of continuous downstream processing (higher resin utilization, smaller column volumes, lower buffer consumption) without the full operational complexity and media consumption of continuous perfusion upstream. Economic analysis indicates the hybrid approach provides the best cost-of-goods per gram for commercial manufacturing in many scenarios, particularly when the downstream is the primary cost driver.

At what scale does process intensification become economically attractive?

Process intensification economics are most favorable at commercial scale with high annual demand. At clinical development volumes, the productivity advantage of continuous perfusion is frequently offset by higher media consumption and process complexity costs relative to a well-optimized fed-batch process. As programs scale toward commercial production at hundreds of kilograms per year, the facility footprint reduction and higher bioreactor utilization of continuous manufacturing increasingly favor intensification over expansion of fed-batch capacity.

What is intensified fed-batch and how does its economics compare to full continuous manufacturing?

Intensified fed-batch applies process intensification to a batch format through high inoculation density, concentrated feeds, and perfusion-based N-1 seed train stages, achieving higher peak cell density and final titer than conventional fed-batch without continuous upstream perfusion during production. It provides significant productivity improvements over conventional fed-batch at lower process complexity and media consumption cost than full continuous perfusion, making it an attractive intermediate option for programs not ready to commit to full continuous manufacturing infrastructure.

Articles

The economics of process intensification

Is continuous manufacturing actually cheaper, or just faster? Here is the math.

Written byTrevor J Henderson

| 9 min read

An executive team reviewing a cost-per-gram financial comparison chart in a pharmaceutical manufacturing strategy meeting, evaluating continuous versus fed-batch manufacturing economics.

The economics of process intensification cannot be evaluated against a hypothetical fed-batch baseline; they must be compared against the best-in-class fed-batch process actually available. Continuous manufacturing's economic advantage over a poorly optimized batch process is not informative; its advantage over a 15 g/L fed-batch process with multicolumn chromatography is the relevant benchmark.

Flow (2026)

Listen with Speechify

0:00

9:00

Highlights in this article

Key takeaways
The productivity equation: how intensification changes the output-per-volume math
What does continuous manufacturing actually cost to implement?
Facility footprint and capital efficiency: the most underappreciated benefit
Where does continuous manufacturing win and where does fed-batch still compete?
Operating costs: media, labor, and the utilization factor
How should a program calculate the ROI case for process intensification?

Process intensification promises higher productivity per unit of bioreactor volume, smaller facility footprints, and lower operating costs. But these benefits come with significant upfront investment in new equipment, extended process development timelines, and operational complexity that fed-batch does not face. Whether continuous manufacturing delivers a positive return depends on which costs are counted, at what scale, and against which baseline.

Key takeaways

Compared to an optimized best-in-class fed-batch process with 15 g/L titer and multicolumn chromatography, end-to-end continuous manufacturing can reduce total annual production costs by up to 23%, facility footprint by up to 51%, plastic waste by up to 57%, and CO2 emissions by up to 54%. These improvements are more pronounced under demand fluctuations, where continuous manufacturing's smaller equipment scale and operational flexibility provide additional economic value.

The facility footprint reduction is the most consistent economic benefit of continuous manufacturing: equivalent annual output from a continuous facility occupies 50 to 70% less physical space than a batch facility, reducing construction cost, cleanroom area, and the capital investment required to add manufacturing capacity. For a facility built for continuous manufacturing from the outset, this translates into 30 to 50% lower facility capital cost compared to a conventional batch facility producing the same annual output.

Continuous manufacturing does not eliminate process development investment; it front-loads it substantially. The cell line development, perfusion media optimization, process characterization, and scale-down model qualification required to establish a reliable continuous process are more extensive than for fed-batch. This upfront cost must be recovered through operational savings and productivity gains over the manufacturing lifetime of the process.

The hybrid approach of fed-batch upstream culture combined with continuous downstream capture and polishing chromatography often provides the best cost-of-goods per gram for commercial manufacturing. It captures the productivity advantage of continuous downstream processing without the full operational complexity and media consumption of continuous perfusion upstream.

The ROI case for process intensification is strongest at commercial scale with high annual demand. At clinical development volumes, the productivity advantage of continuous perfusion does not necessarily offset the higher media consumption, more complex process control requirements, and more expensive cell retention hardware relative to a well-optimized fed-batch process.

For the technical foundation of the process economics covered in this article, see the related articles on perfusion bioreactors for high-density cell culture and custom media development for continuous cell lines. For the full process intensification landscape, see the cluster hub on mastering process intensification and continuous bioprocessing.

The productivity equation: how intensification changes the output-per-volume math

The fundamental economic proposition of process intensification is that higher volumetric productivity from a smaller bioreactor produces equivalent output with less capital. A 2025 comprehensive review of continuous manufacturing of recombinant drugs quantified this productivity advantage: continuous manufacturing achieves a 3- to 5-fold increase in volumetric productivity compared to conventional batch processes, and reduces equipment footprint by up to 70%. For a program producing 100 kg of mAb per year, this means a continuous facility might achieve that output from bioreactors totaling 2,000 liters of working volume where a fed-batch facility would require 10,000 liters.

Volumetric productivity, expressed in grams of product per liter of bioreactor volume per day, is the primary metric that drives the capital efficiency argument for intensification. In a fed-batch process, the bioreactor is occupied for the full batch duration including seed train culture, growth phase, production phase, and turnaround time between batches. At a peak cell density of 20 to 30 million cells per milliliter and a final titer of 5 to 10 g/L over a 14-day production run, the volumetric productivity is typically 0.3 to 0.7 g/L/day. A continuous perfusion process running at 50 million cells per milliliter with ongoing product harvest at steady state can achieve volumetric productivities of 1 to 3 g/L/day or higher with well-optimized processes.

This productivity advantage scales directly with the capital efficiency calculation. A bioreactor capable of 2 g/L/day continuous productivity produces the equivalent annual output of three to four fed-batch bioreactors of the same volume running at 0.5 g/L/day. The capital cost of one bioreactor system, even accounting for the cell retention device, media storage, and additional instrumentation required for continuous operation, is substantially less than four equivalent fed-batch bioreactor systems with their associated balance of plant.

What does continuous manufacturing actually cost to implement?

The implementation cost of continuous manufacturing has two components that are often underweighted in simplistic ROI analyses: process development investment and capital premium on continuous equipment. The process development investment for continuous perfusion includes extended cell line characterization to identify a clone with stable perfusion performance over the intended campaign duration, media development and optimization for the specific CSPR and cell density targets of the process, process characterization studies establishing the design space under continuous operating conditions, and scale-down model qualification demonstrating that the small-scale model predicts commercial-scale behavior.

Each of these activities takes longer and costs more than the equivalent work for a fed-batch process, because the design space of a continuous process is more complex. Analysis of intensified fed-batch processes compared to conventional fed-batch confirms that achieving economic feasibility through process intensification requires highly efficient processes, and that the productivity gains from intensification are not automatic; they depend on the quality of the cell line, media, and process development that precedes manufacturing. Programs that underinvest in development work and then attempt to realize the economics of intensification in GMP manufacturing consistently fall short of modeled productivity.

The capital premium for continuous manufacturing equipment relative to an equivalent fed-batch setup includes the cell retention device (alternating tangential flow, tangential flow filtration, or centrifuge-based), additional media storage and delivery infrastructure to supply continuous medium at the required CSPR, enhanced process control systems with continuous process analytical technology instrumentation, and in many cases a higher-specification bioreactor control system to maintain the tighter dissolved oxygen, pH, and feed rate control required in continuous operation. These additions to the capital cost of the continuous bioreactor suite are real but are more than offset by the smaller bioreactor volume required at equivalent annual output.

Facility footprint and capital efficiency: the most underappreciated benefit

The facility footprint reduction from process intensification is consistently the most underappreciated economic benefit in standard ROI analyses because it is a capital cost that never appears: it is the facility that was not built. Economic and sustainability assessment of end-to-end continuous production of mAbs, comparing continuous manufacturing to an optimized best-in-class fed-batch process, confirmed reductions of up to 51% in facility footprint for continuous manufacturing compared to fed-batch producing the same annual output. In facility cost terms, cleanroom space is typically one of the most expensive components of a GMP facility, both to construct and to operate, making a 51% footprint reduction a corresponding reduction in both construction capital and annual operating cost.

This footprint advantage compounds through the full facility cost structure. Smaller cleanrooms mean lower HVAC capital and operating cost. Fewer large bioreactors mean lower installation, qualification, and maintenance cost. Less stainless steel cleaning infrastructure or fewer large single-use vessel changes mean lower consumable and labor cost per batch. The environmental footprint follows the physical footprint: continuous manufacturing at equivalent output generates substantially less plastic waste from disposable components and uses less water and energy per gram of product.

Economic dimension	Continuous manufacturing vs. best-in-class fed-batch	Source and context
Annual production costs	Up to 23% reduction vs. optimized fed-batch at 15 g/L titer with multicolumn chromatography; larger reduction vs. lower-titer fed-batch baseline	Sartorius, Trends Biotechnol 2025 (pubmed 39510853); multiproduct facility producing clinical and commercial lots; improvement amplified under demand fluctuations
Facility footprint	Up to 51-70% reduction in physical space requirement for equivalent annual output	51% from PubMed 39510853 vs. best-in-class fed-batch; up to 70% from PMC12388894 vs. conventional batch; reduction in cleanroom area directly reduces construction and operating cost
Volumetric productivity	3- to 5-fold increase vs. conventional batch processes	PMC12388894 (2025 comprehensive review); allows smaller bioreactor volume to produce equivalent annual output
Plastic waste	Up to 57% reduction in single-use plastic waste vs. best-in-class fed-batch	pubmed 39510853; continuous manufacturing uses fewer large-volume single-use bags per gram of product due to smaller bioreactor volumes and fewer batch changeovers
Facility capital cost	30 to 50% lower facility capital cost compared to traditional batch facility producing the same annual output	PMC12388894; driven primarily by smaller bioreactor suite size and reduced cleanroom area requirement
Fully integrated continuous COGS	$102.2 per gram in base-case scenario at 500L bioreactor scale for fully integrated continuous platform including upstream, downstream, and formulation	pubmed 36109341; base case includes intensified seed expansion, continuous high cell density perfusion, single-pass TFF, single-use technologies

Where does continuous manufacturing win and where does fed-batch still compete?

Not every biopharmaceutical program benefits equally from the transition to continuous manufacturing, and the economic analysis of process intensification must account for the program-specific variables that determine where continuous wins and where fed-batch remains competitive. Economic feasibility analysis of integrated continuous bioprocessing for clinical and commercial antibody manufacture found that the economically optimal strategy changes between clinical development and commercial production, and between small and large portfolio companies. For commercial production from a COG per gram perspective, the hybrid strategy combining fed-batch upstream culture with continuous downstream capture and batch polishing was preferred over fully continuous manufacturing, because it captures most of the downstream productivity benefit without the media consumption cost of continuous perfusion upstream at commercial scale.

Continuous manufacturing wins most clearly at commercial scale with high annual demand, where the productivity advantage of a smaller bioreactor suite running continuously outweighs the higher media consumption cost and more complex process control requirements. For a program producing 500 kg of mAb per year at an existing facility where the batch bioreactor suite is at capacity, adding continuous perfusion capacity is substantially cheaper than adding equivalent fed-batch capacity in new construction.

Fed-batch remains competitive in several specific contexts. For programs at clinical development scale where annual batch volume is low, the simplicity, lower media cost, and well-established regulatory precedent of fed-batch often produces lower total program cost than continuous manufacturing, whose complexity must be paid for at every scale before its productivity advantage is realized at commercial scale. For molecules with aggressive stability degradation during extended perfusion campaigns, the shorter exposure of cells to culture conditions in fed-batch may produce better product quality than an extended continuous run.

Intensified fed-batch, which applies process intensification principles to a fed-batch format through high inoculation density, concentrated feeds, and perfusion-based N-1 seed train stages, represents an intermediate option that recovers much of the productivity benefit of full continuous manufacturing at lower process complexity cost. Research on fed-batch process intensification through high inoculation density approaches confirmed that these intensified fed-batch processes provide sizable boosts in protein yield compared to conventional fed-batch while avoiding the full operational complexity and cell retention hardware investment of continuous perfusion production.

Operating costs: media, labor, and the utilization factor

The operating cost structure of continuous manufacturing differs from fed-batch in three significant ways: media consumption is substantially higher per liter of bioreactor volume per day, labor per gram of product is lower at high utilization, and the cost of a process failure extends across the duration of the continuous run rather than a single batch.

Perfusion media consumption is the primary operating cost concern in continuous manufacturing. A perfusion bioreactor running at a CSPR of 20 picoliters per cell per day at 50 million cells per milliliter consumes the equivalent of one full bioreactor volume of medium per day. For a 1,000-liter production bioreactor running at commercial scale, this means 1,000 liters of specialized perfusion medium per day, 365,000 liters per year. The media cost per gram of product is driven by the medium cost per liter and the product titer per liter, and the economics favor continuous manufacturing only when the productivity gains from high cell density operation are large enough to offset the higher media consumption relative to fed-batch.

Labor cost per gram of product in continuous manufacturing benefits from high bioreactor utilization. A fed-batch bioreactor spends a significant fraction of calendar time in turnaround: cleaning and sterilization for stainless steel systems, or preparation and qualification for single-use systems, before the next batch can begin. A continuous perfusion bioreactor runs continuously for the campaign duration, producing product every day, so the fixed labor costs of facility operation are amortized over more product volume. At high utilization, this advantage is substantial; at low utilization, the continuous facility pays the full fixed labor cost but produces the output of an intermittently used fed-batch facility.

The full economic evaluation of internal manufacturing infrastructure versus CDMO outsourcing for both fed-batch and continuous process intensification programs, including the capital investment analysis and break-even batch frequency modeling, is addressed in the related article on the build vs. buy decision in biomanufacturing.

How should a program calculate the ROI case for process intensification?

An honest ROI calculation for process intensification requires comparing continuous manufacturing to the best-in-class version of the alternative, not to a poorly optimized fed-batch baseline. The Sartorius economic and sustainability assessment explicitly compared continuous manufacturing to an optimized best-in-class fed-batch process with 15 g/L titer and multicolumn chromatography, not to a standard fed-batch process at 3 to 5 g/L. The economic advantage of continuous manufacturing shrinks substantially as the fed-batch comparator improves. Programs evaluating process intensification should benchmark against the fed-batch titer and downstream efficiency they can realistically achieve, not against industry average performance.

The ROI model should include: the cost of process development investment for the continuous process (cell line work, media development, process characterization, scale-down qualification); the capital cost delta for the continuous facility versus an equivalent-output fed-batch facility; the annual operating cost difference including media, labor, consumables, utilities, and waste disposal; and the productivity or quality advantage that justifies any remaining cost premium. This full lifecycle cost model, run across the projected commercial manufacturing horizon, produces the NPV calculation that determines whether the process intensification investment pays back at the required internal rate of return.

The scenarios where continuous manufacturing most reliably delivers positive ROI are: programs at commercial scale with high annual demand where the smaller bioreactor footprint significantly reduces facility capital; programs building new manufacturing capacity where the facility design can be optimized for continuous operation from the start; programs in markets where regulatory pathways for continuous manufacturing are well-established; and programs where supply chain agility (the ability to rapidly scale production up or down in response to demand changes) has strategic value that is captured in the business model.

This article was produced under Drug Discovery News' AI Editorial Guidelines.

Frequently Asked Questions (FAQs)

How much cheaper is continuous manufacturing than fed-batch?
Compared to an optimized best-in-class fed-batch process at 15 g/L titer with multicolumn chromatography, end-to-end continuous manufacturing reduces total annual production costs by up to 23%, facility footprint by up to 51%, and facility capital cost by 30 to 50%. The advantage is larger when the comparison is against a lower-titer fed-batch baseline. These figures come from economic modeling of a multiproduct facility producing clinical and commercial lots; actual savings depend on program-specific titer, scale, and demand profile.
What is the main cost disadvantage of continuous manufacturing versus fed-batch?
Perfusion media consumption is the primary operating cost disadvantage. A continuous perfusion bioreactor running at steady state consumes roughly one full bioreactor volume of medium per day, meaning a 1,000-liter bioreactor uses 365,000 liters of specialized perfusion medium per year. This cost is offset by the higher volumetric productivity of the smaller bioreactor, but the net economic balance depends on the product titer, media cost per liter, and the annual volume being produced.
What is the hybrid approach to process intensification and when is it preferred?
The hybrid approach combines fed-batch upstream cell culture with continuous downstream capture and polishing chromatography. It captures the productivity gains of continuous downstream processing (higher resin utilization, smaller column volumes, lower buffer consumption) without the full operational complexity and media consumption of continuous perfusion upstream. Economic analysis indicates the hybrid approach provides the best cost-of-goods per gram for commercial manufacturing in many scenarios, particularly when the downstream is the primary cost driver.
At what scale does process intensification become economically attractive?
Process intensification economics are most favorable at commercial scale with high annual demand. At clinical development volumes, the productivity advantage of continuous perfusion is frequently offset by higher media consumption and process complexity costs relative to a well-optimized fed-batch process. As programs scale toward commercial production at hundreds of kilograms per year, the facility footprint reduction and higher bioreactor utilization of continuous manufacturing increasingly favor intensification over expansion of fed-batch capacity.
What is intensified fed-batch and how does its economics compare to full continuous manufacturing?
Intensified fed-batch applies process intensification to a batch format through high inoculation density, concentrated feeds, and perfusion-based N-1 seed train stages, achieving higher peak cell density and final titer than conventional fed-batch without continuous upstream perfusion during production. It provides significant productivity improvements over conventional fed-batch at lower process complexity and media consumption cost than full continuous perfusion, making it an attractive intermediate option for programs not ready to commit to full continuous manufacturing infrastructure.

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Trevor J Henderson
Trevor Henderson is the Creative Services Director for the Laboratory Products Group at LabX Media Group. With over two decades of experience, he specializes in scientific and technical writing, editing, and content creation. His academic background includes training in human biology, physical anthropology, and community health. Since 2013, he has been developing content to engage and inform scientists and laboratorians.
View Full Profile